Dr. Amanda Nizam

So the question now is, how do we treat up?

Well, will be.

Once we see the DV PEMBRO data, will be how do we treat up front, localize it,

locally advanced and metastatic patients who do have HER2 or, you know, at least one plus disease, depending on the results, how do we treat those patients when you have EV Pembro and other things?

We're also going to see other, you know, there are other trials, the FORAGER, which is going to have the FGFR3 with EV Pembro up front.

So it'll be interesting to see how the upfront locally advanced and metastatic setting evolves over the next couple of years as well.

Yeah.

So as you both know, HER2 and Nectin-4 are usually co-expressed quite frequently.

So that is an important question.

At ASCO-GU, you will see some data from UNITE on EV-Pembro outcomes in patients with HER2-positive disease.

So we'll see that probably in some real-world data.

And then from there, that'll be the question once we see the DV-Pembro data is what to do.

Yes.

There's a subset for sure.

There are still, you know, 10% of patients who do have primary progression, and we need to figure out who those patients are.

And we'll be looking at, we're actually looking at that in UNITE as well.

But ideally, we would get that data from a prospective clinical trial.

The important thing is to identify those patients who are not going to respond to upfront Evpembro.

And then those patients, I think, you know, we can't forget about these patients with the less common subtype histologies, like the micropapillary, the, you know, the nested variants, the squamous cell.

You know, we really need to start doing more trials in those populations.